Healthcare Global Enterprises Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Healthcare Global Enterprises Limited (HCG) has filed a compliance statement under Regulation 32 of SEBI LODR Regulations confirming no deviations or variations in the utilisation of proceeds from its Rights Issue. The company raised INR 424.68 crore through a Rights Issue with allotment on March 27, 2026. The funds were allocated for: pre-payment/repayment of borrowings (Rs 170 crore), part-payment for acquiring additional 34% stake in Vizag Hospital and Cancer Research Center Private Limited (Rs 154.04 crore), general corporate purposes (Rs 95.57 crore), and issue expenses (Rs 5.07 crore). The filing states zero utilisation and zero deviation for the quarter. The statement was reviewed by the Audit Committee with no comments. CARE Ratings Limited is the monitoring agency. Since the Rights Issue allotment occurred just days before quarter-end (March 27, 2026), minimal or zero utilisation is expected as funds may not have been deployed yet.
This is a routine regulatory compliance filing with no immediate shareholder impact. The confirmation of zero deviation provides assurance that the company is deploying rights issue proceeds as originally stated in the Letter of Offer. The nil utilisation for the first quarter post-allotment is normal given the timing.